Prince Charles gives a speech at AstraZeneca's Discovery Centre (DISC) unveiling, with Pascal Soriot

Eight years and $1.3B lat­er, As­traZeneca fi­nal­ly un­veils Cam­bridge R&D palace

One of the biggest projects that Pas­cal So­ri­ot ini­ti­at­ed, all the way back in 2013, af­ter he first took over as As­traZeneca’s CEO is fi­nal­ly com­plete.

Su­san Gal­braith

As­traZeneca is for­mal­ly un­veil­ing its $1.34 bil­lion (£1 bil­lion) R&D cam­pus in Cam­bridge, UK, a shiny new fa­cil­i­ty span­ning 19,000 square me­ters in the south­ern part of the city. On top of 2,200 re­search sci­en­tists, it will al­so host a suite of ro­bot­ics, high-through­put screen­ing and AI-dri­ven tech­nol­o­gy.

“I think it’s a very bold state­ment that we’ve got the new build­ing,” Su­san Gal­braith, EVP of on­col­o­gy R&D, said in a video, “be­cause it’s ba­si­cal­ly say­ing that R&D is the fu­ture of the com­pa­ny, and that we want to in­vest in hav­ing the best fa­cil­i­ties pos­si­ble for peo­ple to do in­no­v­a­tive sci­ence. So that it­self I think is a state­ment of in­tent for what we want the fu­ture of the com­pa­ny to be.”

From pre­ci­sion med­i­cines to next-gen treat­ments such as nu­cleotide-based, gene-edit­ing and cell ther­a­pies, the com­pa­ny has high hopes for the site, which it’s call­ing the Dis­cov­ery Cen­tre (DISC).

When As­traZeneca first an­nounced plans to build the new glob­al R&D hub and cor­po­rate head­quar­ters, the goal was to be ready for move-in by 2016 on a bud­get of $500 mil­lion. So­ri­ot’s vi­sion was for the team to be­come an in­te­gral part of the lo­cal ecosys­tem in Cam­bridge, “a world-renowned bio­science hotspot that ri­vals the likes of San Fran­cis­co and Boston.”

As­traZeneca’s new R&D cen­ter in Cam­bridge, UK (Hufton + Crow)

Click on the im­age to see the full-sized ver­sion

In the end, it was just like de­vel­op­ing a new drug. Fraught with high costs, dis­ap­point­ing set­backs and the source of bit­ter crit­i­cism.

Andy Williams

But the de­lays didn’t stop As­traZeneca from ink­ing over 200 col­lab­o­ra­tions in the re­gion, in­clud­ing 130-plus with the Uni­ver­si­ty of Cam­bridge, on top of more than 2,000 around the world, ac­cord­ing to Andy Williams, VP of Cam­bridge pro­gram and strat­e­gy. And the open-floor de­sign of the new build­ing will hope­ful­ly deep­en these ties while fos­ter­ing more.

The grand open­ing on Tues­day fea­tures Prince Charles as the guest of hon­or.

Lo­cat­ed with­in the Cam­bridge Bio­med­ical Cam­pus, As­traZeneca is now neigh­bors with mul­ti­ple re­search hos­pi­tals as well as Ab­cam, the re­search tool provider.

At the In­flec­tion Point for the Next Gen­er­a­tion of Can­cer Im­munother­a­py

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.

All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at FDA; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

The slate of products we’re offering here at Endpoints is continuing to grow, and it’s not just limited to editorial. If you haven’t, do visit your reader profile to see if there are any other weekly newsletters you’re interested in — as each comes with its own exclusive content. And don’t miss the publisher’s note from Arsalan Arif on Endpoints Studio, our latest avenue for advertising on Endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Usama Malik

Ex-Im­munomedics CFO charged with in­sid­er trad­ing, faces up to 20 years in prison af­ter al­leged­ly tip­ping off girl­friend and rel­a­tives of a PhI­II suc­cess

The former CFO of Immunomedics, who helped steer the company to its $21 billion buyout by Gilead last year, has been charged with insider trading, the Department of Justice announced Thursday.

Usama Malik tipped off his then-girlfriend and four others that a Phase III study for Trodelvy would be stopped early four days before Immunomedics publicly announced the result in April 2020, DoJ alleged in its complaint. The individuals then purchased Immunomedics shares, selling them after the news broke and Immunomedics’ stock price doubled.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Merck's new antiviral molnupiravir (Quality Stock Arts / Shutterstock)

As Omi­cron spread looms, oral an­tivi­rals ap­pear to be one of the best de­fens­es — now we just need more

After South African scientists reported a new Covid-19 variant — dubbed Omicron by the WHO — scientists became concerned about how effective vaccines and monoclonal antibodies might be against it, which has more than 30 mutations in the spike protein.

“I think it is super worrisome,” Dartmouth professor and Adagio co-founder and CEO Tillman Gerngross told Endpoints News this weekend. Moderna CEO Stéphane Bancel echoed similar concerns, telling the Financial Times that experts warned him, “This is not going to be good.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Common performs onstage, December 2020 (Getty Images)

Com­mon, Jamie Foxx among celebs stand­ing up for clin­i­cal tri­als in star-stud­ded can­cer group's pan­dem­ic push

Healthcare screenings and clinical trial enrollment were battered by the pandemic. But the well-known celebrity-backed Stand Up To Cancer non-profit, along with pharma and advocacy partners, has been working to reverse that and make up lost ground, by stepping up awareness campaigns.

Twelve campaigns launched in 2020 and another five in 2021 amplify the need for cancer screening and care, especially for underserved communities. While pharma companies have long been donors to the cancer research group, Covid brought new support — and increased awareness efforts.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Am­gen halts some drug dis­counts for safe­ty net hos­pi­tals as SCO­TUS takes on 340B case

Amgen will soon be the 10th biopharma company to pull back on offering drug discounts to contract pharmacies of safety-net hospitals under a federal program. Like its peers, Amgen argues that the growth of these contract pharmacies has ballooned in recent years and needs to be reigned in.

Beginning Jan. 3, 2022, Amgen’s policy will only allow 340B covered hospitals to designate a single pharmacy location, with the exception of federal grantees and contract pharmacies wholly owned by a 340B hospital, or that have common ownership with a health system.

In­cor­po­rat­ing Ex­ter­nal Da­ta in­to Clin­i­cal Tri­als: Com­par­ing Dig­i­tal Twins to Ex­ter­nal Con­trol Arms

Most drug development professionals are familiar with the nerve-racking wait for the read-out of a large trial. If it’s negative, is the investigational therapy ineffective? Or could the failure result from an unforeseen flaw in the design or execution of the protocol, rather than a lack of efficacy? The team could spend weeks analyzing data, but a definitive answer may be elusive due to insufficient power for such analyses in the already completed trial. These problems are only made worse if the trial had lower enrollment, or higher dropout than expected due to an unanticipated event like COVID-19. And if a trial is negative, the next one is likely to be larger and more costly — if it happens at all.

What's fair? New ICER re­port shows pay­ers gen­er­al­ly en­sur­ing fair ac­cess to drugs

The nonprofit Institute for Clinical and Economic Review on Wednesday released a new report highlighting the ways in which payers are generally ensuring fair access to prescription drugs, even when based on a set of criteria set by the nonprofit.

While noting the lack of transparency hindered the report’s results, ICER said that the “great majority” of payer policies in the formularies evaluated are structured in a way to support many key elements of how ICER defines “fair access.”

Ab­b­Vie tacks on a new warn­ing to Rin­voq la­bel as safe­ty frets crimp JAK class

The safety problems that continue to plague the JAK class as new data highlight some severe side effects are casting a large shadow over AbbVie’s Rinvoq.

As a result of a recent readout highlighting major adverse cardiac events (MACE), malignancy, mortality and thrombosis with Xeljanz a couple of months ago, AbbVie put out a notice late Friday afternoon that it is adding the new class risks to its label for their rival drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.